Compass Therapeutics, Inc. Common Stock CMPX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T13:48:49.500Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T12:29:06.99297189Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:48:49.063278+00:00
Compass Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.48 | 236.4% | 72.9% | |||
| 25Δ | 1.13 | 152.4% | 33.0% | |||
| 30Δ | 0.97 | 140.4% | 17.1% | |||
| 35Δ | 0.93 | 174.1% | 16.4% | |||
| 40Δ | 0.89 | 207.8% | 15.6% | |||
| 45Δ | 0.85 | 241.5% | 14.9% | |||
| 50Δ | 0.81 | 275.2% | 14.2% | |||
| 55Δ | 0.76 | 308.8% | 13.5% | |||
| 60Δ | 0.72 | 342.5% | 12.7% | |||
| 65Δ | 0.68 | 376.2% | 12.0% | |||
| 70Δ | 0.64 | 409.9% | 11.3% | |||
| 75Δ | 0.59 | 443.6% | 10.6% | |||
| 80Δ | 0.55 | 477.3% | 9.8% | |||
20Δ
- Pseudo strike
- 1.48
- IV
- 236.4%
- B/E move
- 72.9%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 1.13
- IV
- 152.4%
- B/E move
- 33.0%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 0.97
- IV
- 140.4%
- B/E move
- 17.1%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 0.93
- IV
- 174.1%
- B/E move
- 16.4%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 0.89
- IV
- 207.8%
- B/E move
- 15.6%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 0.85
- IV
- 241.5%
- B/E move
- 14.9%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 0.81
- IV
- 275.2%
- B/E move
- 14.2%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 0.76
- IV
- 308.8%
- B/E move
- 13.5%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 0.72
- IV
- 342.5%
- B/E move
- 12.7%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 0.68
- IV
- 376.2%
- B/E move
- 12.0%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 0.64
- IV
- 409.9%
- B/E move
- 11.3%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 0.59
- IV
- 443.6%
- B/E move
- 10.6%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 0.55
- IV
- 477.3%
- B/E move
- 9.8%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe…
More →COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge,…
More →CORT
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company…
More →COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is…
More →CRBP
Description unavailable
More →CRBU
Description unavailable
More →